

Frequency of Methicillin-resistant *Staphylococcus aureus* isolates from Clinical Specimens in Gondar University Hospital, Northwest Ethiopia

¹Belay Anagaw, ¹Yitayal Shiferaw, ²Berhanu Anagaw, ^{3,4}Fantahun Biadlegne, ¹Feleke Moges, ¹Afewerk Kassu, ¹Chandrashekhhar Unakal and ^{1,5}Andargachew Mulu

¹Department of Medical Microbiology, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia

²Faculty of Sciences, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia

³Faculty of Medicine and Health Sciences, Bahir Dar University, P.O. Box 79, Bahir Dar, Ethiopia

⁴Institute of Medical Microbiology and Epidemiology of Infectious Diseases, Faculty of Medicine, University of Leipzig, Leipzig, Germany

⁵Institute of Virology, Faculty of Medicine, University of Leipzig, Germany

Abstract: The development of resistance to multiple antibiotics and control of disease transmission by MRSA isolates in hospitals/communities have been recognized as the major challenges as the bacterial population that expresses the resistance phenotype varies according to the environmental conditions. This study was conducted to determine the magnitude of MRSA strain and to investigate the *in vitro* antimicrobial susceptibility pattern and β -lactamase production of strains isolated from clinical specimens. Total of 1,295 clinical specimens including: pus, wound swab and discharge and body fluids were collected from patients presenting with infection. The presence of *Staphylococcus aureus* was detected using conventional microbiological methods. Isolated *S. aureus* were further subjected to MRSA screening and subsequently the antibiotic susceptibility test was performed. The data were entered and analyzed using SPSS. Of the total 279 *S. aureus* isolates during the study period (21.5%), 49 (17.6%) were found to be MRSA. Most of MRSA were isolated from wound swab and discharge and from inpatient. All MRSA strains recorded susceptibility to vancomycin, flucloxacillin, cefadroxil and ceftiofur, which was followed by 95.9% to clindamycin. In contrast, all strains of MRSA were found to be resistance to penicillin and 78.7% of them were found to be multidrug resistant. Both β -lactamase productions were detected in all *S. aureus* irrespective of methicillin-resistant. According to this study, vancomycin, flucloxacillin, cefadroxil and ceftiofur seems to be most effective antimicrobial agents which shows 100% sensitivity even with multi-drug resistance.

Keywords: Clinical specimens, frequency, gondar ethiopia, MRSA, *Staphylococcus aureus*

INTRODUCTION

Staphylococcus aureus is a common cause of community and hospital acquired infections. It is associated with infections in all age groups, including surgical wounds, skin abscess, osteomyelitis, septicemia, food poisoning and toxic shock syndrome (Jawetz *et al.*, 2007). Over the past 50 years, treatment of these infections has become more difficult because of the emergence and spread of resistance to various antibiotics (Jun *et al.*, 2004). The most notable example of this phenomenon was the emergence of methicillin resistant *Staphylococcus aureus* (MRSA), which was reported just one year after the use of methicillin (Qureshi *et al.*, 2004; Cookson *et al.*, 2003). Methicillin resistance in staphylococci is mediated by the *mecA* gene, which encodes for the Penicillin-Binding Protein 2A (PBP2A) resulting in reduced affinity for the beta-

lactam antibiotics including the penicillinase-resistant penicillin and thus it become a major hospital pathogen in human medicine (Rohrer *et al.*, 2003). Since, the emergences of MRSA there have been many reports of MRSA causing various infections throughout the world. MRSA is of concern not only because of its resistance to methicillin but also many of these MRSA isolates are becoming multidrug resistant and are susceptible only to glycopeptides antibiotics such as vancomycin (Mehta *et al.*, 1998). Indeed, low level resistance even to vancomycin is emerging at present (Assadullah *et al.*, 2003). The prolonged hospital stay, indiscriminate use of antibiotics, lack of awareness, receipt of antibiotics before coming to the hospital are the possible predisposing factors for the emergence of MRSA (Anupurba *et al.*, 2003).

The magnitude of MRSA infections has been increased in the past decades worldwide. For example it

has increased from 2.0% in 1974 to 22.0% in 1995 and to 63.0% in 2004 in USA (CDC, HA-MRSA 2010). Similarly, it has increased from 29% to 42.5% in India (Metha *et al.*, 1996; Chandrashekhara and Basappa, 2012). Although studies in Africa are limited, previous reports showed high rate of MRSA infection (Hayanga *et al.*, 1997; Omari *et al.*, 1997; Urassa *et al.*, 1999). In Ethiopia, similar to other African countries little is known on the magnitude of MRSA. However, previous studies in the country have shown the importance of *S. aureus* in diseases and the emergency of multiple drug resistance strains with 19% MRSA (Yohannes *et al.*, 1999; Beyene and Abdissu, 2000; Aseffa and Yohannes, 1996; Moges *et al.*, 2002a, b). The development of resistance to multiple antibiotics and control of disease transmission by MRSA isolates in hospitals and/ or in communities have been recognized as the major challenges as the bacterial population that expresses the resistance phenotype varies according to the environmental conditions (McDonald, 1997; Qureshi *et al.*, 2004). And since methicillin disc is used as a representative of the group of penicillinase resistant penicillin including oxacillin, cloxacillin, nafcillin, flucloxacillin and dicloxacillin isolation of MRSA is useful for in clinical practice to appropriately select antibiotics. Therefore, it is imperative to know the magnitude of MRSA and their current antimicrobial profile in areas where drug susceptibility testing is lacking. In the present study, we determined the magnitude of MRSA strain in different clinical specimens and define the in vitro antimicrobial susceptibility pattern and β -lactamase production of strains isolated from patients at Gondar University hospital, North West Ethiopia.

MATERIALS AND METHODS

Source of specimens: A total of 1,295 clinical specimens including: Pus, wound swab and discharge and body fluids were collected for *Staphylococcus aureus* screening from in and out patients of University of Gondar Teaching Hospital. These specimens were collected from September 2009 to June 2010 and analyzed in Microbiology Laboratory of Gondar University Teaching Hospital. The specimens were collected as part of routine clinical management of patients both from in-patient and out-patient with various clinical profiles. Specimens were collected following standard procedures for specimen collection (Cheesbrough, 2002).

Isolation and identification of clinical specimens: All the specimens were aseptically handled and processed. The morphotypes were done for all the specimens based on the Gram staining method to determine the likely organism present. Subsequently, the clinical specimens were inoculated on to 10% sheep blood agar, mannitol

salt agar, MacConkey agar and nutrient agar and incubated at 37°C for 24 hours. Initial screening and identification of *S. aureus* were done according to standard laboratory protocols where colonial morphology, Gram's stain reaction and biochemical characteristics were used for identification of *S. aureus*. *Staphylococcus aureus* ATCC 25923 of known coagulase production was included as control strain. Isolates that were gram-positive cocci, catalase positive, coagulase positive and mannitol fermentation were considered as *S. aureus* in this study.

Antimicrobial susceptibility test: Drug susceptibility test for each *S. aureus* isolates were carried out following the standard agar disc diffusion methods. Briefly, 3-4 morphologically identical colonies of *S. aureus* were picked up by sterile inoculating loop and suspended in about 3ml of nutrient broth with sterile normal saline to a turbidity that matches to 0.5 McFarland standard (approximately contains 10^7 to 10^8 CFU/ml). A sterile absorbent cotton swab was immersed into the bacterial suspension and rolled on the wall of the tube and then inoculated on Muller Hinton agar (Oxoid Ltd; Basingstoke, Hampshire, England) uniformly in aseptic condition. The plates were then incubated at 35°C for 24 h so as to favor the growth of methicillin-resistant strains. Susceptibility testing was done for methicillin (5 μ g) and others antimicrobials including chloramphenicol (30 μ g), penicillin G (30 μ g), ampicillin (30 μ g), amoxicillin (30 μ g), tetracycline (30 μ g), gentamicin (10 μ g), erythromycin (15 μ g), co-trimoxazole (25 μ g), ciprofloxacin (5 μ g), ceftriaxone (30 μ g), clindamycin (30 μ g), flucloxacillin (5 μ g), cefadroxil (30 μ g), cefoxitin (30 μ g) and vancomycin (10 μ g). The antimicrobial susceptibility tests were interpreted based on the recommendation of the Clinical and Laboratory Standards Institute (CLSI). A zone of inhibition of less than 10 mm or any discernible growth within the zone of inhibition was taken as indicative of methicillin resistance (screening out MRSA strains) and for the others antimicrobials the diameter of zone of inhibition produced by each antibiotic disc was measured, recorded and the isolates were classified as "resistant", "intermediate" and "sensitive" based on the standard interpretative chart updated according to the current CLSI standard (NCCLS, 2002). Reference strains of *S. aureus* (ATCC 25923) was tested regularly and methicillin-resistant and methicillin-sensitive strain were included as controls according to the CLSI.

Detection of β -lactamase production: β -lactamase production was determined by acidimetric filter paper test. Briefly, benzylpenicillin was dissolved in phosphate buffer (pH8) and then bromocresol purple indicator solution was added and mixed. The mixture then placed in a strip of Whatman filter paper (number 1)

and kept in the bottom of a Petri dish. After the paper is fully saturated a few drops of buffered crystalline penicillin bromocresol purple solution was added. Using a sterile wire loop, few colonies from the medium plate were transferred to the filter paper. If the color of the paper changes in 60 min incubation period, the bacteria were considered as beta-lactamase positive.

Data analysis: All data were registered in laboratory logbook during the study period. Then the data were entered and analyzed using SPSS statistical software package (version 16) and a p-value <0.05 was considered statistically significant.

Ethical consideration: Ethical approval was obtained from Ethical Review Committee of the University of Gondar.

RESULTS

Bacteriological isolates: A total number of 279 *S. aureus* were isolated. The highest percentage of these isolates were collected from pus specimens and the least number of isolates were recovered from eye discharge (Table 1). The isolation rates of methicillin

resistance were found to be 17.6% (49/279). The prevalence of MRSA was significantly different among various clinical specimens ($p < 0.05$) and was found that 24.2% of these isolates were from wound swab and discharges, followed by pus (14.6) and 0% from eye discharge. The number of MRSA isolates were significantly different between in-patient and outpatient ($X^2 = 7.81$; 95% CI = 1.286, 4.504; $p = 0.005$) (Table 2).

Antimicrobial susceptibility test: All the 49 MRSA isolates were resistant to penicillin, 93.9% to ampicillin, amoxicillin, chloramphenicol and co-trimoxazole each, 40.8% to tetracycline, 36.7% to erythromycin and 24.5% to gentamicin. However, all MRSA strains were found to be susceptible to vancomycin, flucloxacillin, cefadroxil and ceftioxin, which was followed by 95.9% to clindamycin. In contrast, 83.9% of methicillin sensitive *S. aureus* (MSSA) were resistant to penicillin and ampicillin, 56.5% resistance to amoxicillin, 39.6% resistance to tetracycline, 13.0% resistance to chloramphenicol and co-trimoxazole, 9.6% resistance to erythromycin, 1.3% resistance to gentamicin as compared with MRSA (Table 3).

Table 1: Number and percentage distribution of MRSA from different clinical specimens at university of Gondar teaching hospital, Gondar, Ethiopia from September, 2009 to June, 2010

Clinical specimens	Total specimens (N = 1295)	<i>S. aureus</i> (n = 279)	%	MRSA (n = 49)	%
Wound swab and discharge	320	120	37.5	29	24.2
Pus	210	89	42.4	13	14.6
Body fluid	115	11	9.6	1	9.1
Genital swabs	85	13	15.3	1	7.7
Ear discharge	200	30	15.0	3	10.0
Eye discharge	150	2	1.3	0	0.0
Urine	215	14	6.5	2	14.3

N = Total number of specimens processed, n = individual number of isolates

Table 2: Distribution of *S. aureus* and MRSA based on source of specimens at university of Gondar teaching hospital, Gondar, Ethiopia from September, 2009 to June, 2010

Specimen source	Total specimens (N = 1259)	<i>S. aureus</i> n (%)	MRSA n (%)	X^2	P-value	95%CI
In-patient	660	110 (16.7)	28 (25.6)	7.81	0.005	1.286, 4.504
Out-patient	635	169 (26.6)	21 (12.4)			

N = total number of specimens processed, n = individual number of isolate, X^2 = chi-square

Table 3: Antimicrobial susceptibility pattern of MRSA and MSSA isolated at University of Gondar teaching hospital, Gondar, Ethiopia from September, 2009 to June, 2010

Antimicrobials	MRSA (n = 49)			MSSA (n = 230)			Total (N = 279) No of resistance rate (%)
	No of isolates that were		Resistance rate (%)	No of isolates that were		Resistance rate (%)	
	S	R		S	R		
Penicillin G	0	49	100.0	37	193	83.9	242(86.7)
Ampicillin	3	46	93.9	43	187	81.3	233(83.5)
Amoxicillin	3	46	93.9	100	130	56.5	176(63.1)
Chloramphenicol	3	46	93.9	200	30	13.0	76(27.2)
Co-trimoxazole	3	46	93.9	200	30	13.0	76(27.2)
Erythromycin	31	18	36.7	208	22	9.6	40(14.3)
Gentamicin	37	12	24.5	227	3	1.3	15(5.4)
Tetracycline	29	20	40.8	139	91	39.6	111(39.8)
Ciprofloxacin	45	4	8.2	230	0	0.0	4(1.4)
Ceftriaxone	46	3	6.1	230	0	0.0	3(1.1)
Vancomycin	49	0	0.0	230	0	0.0	0(0.0)
Clindamycin	47	2	4.1	230	0	0.0	2(0.7)
Flucloxacillin	49	0	0.0	230	0	0.0	0(0.0)
Cefadroxil	49	0	0.0	230	0	0.0	0(0.0)
Ceftioxin	49	0	0.0	230	0	0.0	0(0.0)

N = Total number of *S. aureus* isolates, n = individual number of isolates

Table 4: Multi-drug resistance and β -lactamase production from *Staphylococcus aureus* isolates at university of Gondar teaching hospital, Gondar, Ethiopia from September, 2009 to June, 2010

<i>S. aureus</i> isolates	β -lactamase (N = 230)		
	Producing (n = %)	Non- producing (n = %)	MDR (n = %)
MRSA	49 (100.0)	0 (0.0)	39 (79.6)
MSSA	181 (78.7)	49 (21.3)	92 (40)
Total	230 (82.4)	49 (17.6)	131 (47%)

N = total number of β -lactamase, n = individual number, MDR = multi-drug resistance

Detection of multi-drug resistance and β -lactamase production: All the 49 MRSA isolates was found to be of β -lactamase producing strains. Of which 79.6% (39/49) showed multidrug resistance. Among the 230 MSSA isolates, 78.7% were beta-lactamase positive (Table 4). Further analysis indicated significant rate of multi-drug resistance ($X^2 = 25$; 95% CI = 0.081, 0.359; $p = 0.0001$) and β -lactamase ($X^2 = 12.4$; 95%CI=1.183, 1.350; $p = 0.001$) production observed among MRSA compared to MSSA.

DISCUSSION

The data in the present study shows a frequent isolation of MRSA in inpatients and is comparable with previous studies from African (Bouchillon *et al.*, 2004; Zinn *et al.*, 2004) and Asian countries (Sanjana *et al.*, 2010; Saikia *et al.*, 2009; Rajadurai pandi *et al.*, 2006). We have observed that the resistant rate to different antibiotics among MRSA strains was higher than those sensitive to methicillin and this phenomena was reported elsewhere (Tahnkiwale *et al.*, 2002). In this study all the strains showed susceptibility to vancomycin, flucloxacillin, cefadroxil and cefoxitin and most of them were susceptible to clindamycin and ceftriaxone. This report was in line with the studies conducted in Nepal (Rajadurai pandi *et al.*, 2006), Trinidad & Tobago (Patrick *et al.*, 2006), Addis Ababa (Yohannes *et al.*, 1999) and in middle Tennessee (Kilic *et al.*, 2006). All MRSA isolates were significantly less sensitive to antibiotics as compared with MSSA isolates. As expected, all the strains were resistant to penicillin and most of them were resistant to ampicillin which was not observed in case of MSSA. This report was similar with the studies conducted in Trinidad and Tobago (Patrick *et al.*, 2006) and Nepal (Zinn *et al.*, 2004). Lower penicillin resistance of 80% also was observed in India (Sanjana *et al.*, 2010). The present study also showed that relatively high antibiotic resistance profile of MRSA to the commonly used antibiotics like, amoxicillin, chloramphenicol and cotrimoxazole (93.9% each) and 40.8% of tetracycline. In one study on spectrum of antimicrobial resistance among MRSA, ciprofloxacin resistance was as high as 90% and Qureshi had reported the same as 98.9 %

(Qureshi *et al.*, 2004; Pulimood *et al.*, 1996). In contrast, we have 8.2% of the strains resistant to ciprofloxacin. These discrepancies may result from the low number of methicillin-resistant isolates collected for our study, may be due to overuse of the drugs since ciprofloxacin prescribed in our study as final option and finally may be due to misuse of drugs. However, Pulimood had observed only 8% resistance of MRSA to gentamicin (Pulimood *et al.*, 1996) as against 24.5% in our study. Gentamicin resistance is on the rise since 1996. An increase of gentamicin resistance from 0% before 1996 to 80% after 1996 has been reported (Price *et al.*, 1998). Qureshi had reported a gentamicin resistance of 97.8% (Qureshi *et al.*, 2004), which is higher compared to our study. Many of MRSA (79.6%) strains were multidrug resistant (resistance of two and more antibiotics) compared to MSSA (40%). Higher percentages of multidrug resistant were also reported from different studies (Saikia *et al.*, 2009; Majumder *et al.*, 2001). Similarly we observed all MRSA strains were produce β -lactamase which help the bacteria to develop multiple drug resistance pattern for β -lactam antibiotics including penicillin and its derivatives as compared to that of MSSA strains which was more sensitive for these drugs. Identical finding was also reported from other similar studies (Paradisi *et al.*, 2001; Olowe *et al.*, 2007).

In conclusion, the emergence of multi-drugs resistance in MRSA is worrisome in the present study and more cases were identified among inpatients. A regular surveillance of hospital associated infection including monitoring antibiotic sensitivity pattern is mandatory to controlling the spread in the hospital and strict drug policy are of importance or else the threat will increase. According to this study, vancomycin, flucloxacillin, cefadroxil and cefoxitin seems to be most effective antimicrobial agents in our area which shows 100% sensitivity even with multi drug resistance. These drugs remains the first choice of treatment for MRSA and to preserve their value, their use should be limited to those cases where there are clearly needed. Further detection and molecular characterization of the gene (*mec A*), phage typing and analyses of the plasmids of MRSA is necessary.

Declaration of competing interests: The author (s) declares that they have no competing interests.

Authors' contributions: BA, AM, FM, AK &YS designed the study, carried out the testing, performed the statistical analysis and interpretation of data and drafted the manuscript. BA participated in statistical analysis. YS, CU and FB conceived the study, participated in antibiotic testing and in the preparation of the settings. All authors read and approved the final manuscript.

ACKNOWLEDGMENT

The authors are indebted to the University of Gondar Teaching Hospital Bacteriology Laboratory staffs for their co-operation and facilities during the study period.

REFERENCES

- Anupurba, S., M.R. Sen, G. Nath, B.M. Sharma, A.K. Gulati and T.M. Mohapatra, 2003. Prevalence of methicillin resistant *Staphylococcus aureus* in a tertiary care referral hospital in Eastern Uttar Pradesh. *Ind. J. Med. Microbiol.*, 21: 49-51.
- Aseffa, A. and G. Yohannes, 1996. Antibiotic sensitivity pattern of prevalent bacterial pathogens in Gondar, Ethiopia. *East Afr. Med. J.*, 73(1): 67-71.
- Assadullah, S., D.K. Kakru, M.A. Thoker, F.A. Bhat, N. Hussai and A. Shah, 2003. Emergence of low level vancomycin resistance in MRSA. *Ind. J. Med. Microbiol.*, 21: 196-198.
- Beyene, G. and T. Abdissu, 2000. Common bacterial pathogens and their antibiotic sensitivity at Jimma hospital: A four year retrospective study. *Eth. J. Health Sci.*, 10(2): 129-136.
- Bouchillon, S.K., B.M. Johnson, D.J. Hoban, J.L. Johnson, M.J. Dowzicky, D.H. Wu, M.A. Visalli and P.A. Bradford, 2004. Determining incidence of extended spectrum β -lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant *Staphylococcus aureus* in 38 centres from 17 countries: The PEARLS study 2001-2002. *Int. J. Antimicrob. Agents*, 24: 119-124.
- Chandrashekhar, U. and K. Basappa, 2012. Phenotypic characterization and risk factors of nosocomial *Staphylococcus aureus* from health care centers. *Adv. Microbiol.*, 2: 122-128.
- Cheesbrough, M., 2002. *District Laboratory Practice in Tropical Countries. Part II*; Cambridge University Press, UK, pp: 136-142.
- Cookson, B., F. Schmitz and A. Fluit, 2003. Introduction. In: Fluit, A.C. and F.J. Schmitz (Eds.), *MRSA: Current Perspectives*. Caister Academic Press, Wymondham, pp: 1-9.
- Hayanga, A., A. Okello, R. Hussein and A. Nyong'o, 1997. Experience with MRSA at Nariobi Hospital. *East Afr. Med. J.*, 74: 203-204.
- Jawetz, Melnick and Adelbergis, 2007. *Medical Microbiology*. 24th Edn., McGraw Hills Co., Inc, USA, pp: 224-230.
- Jun, I.S., F. Tomoko, S. Katsutoshi, K. Hisami, N. Haruo, K. Akihiko, A.H. Qureshi and S. Rafi, 2004. Prevalence of erythromycin, tetracycline and aminoglycoside-resistance genes in methicillin-resistant *Staphylococcus aureus* in hospitals in Tokyo and Kumamoto. *Jpn. J. Infect. Dis.*, 57: 75-77.
- Kilic, A., H. Li, C.W. Stratton and Y.W. Tang, 2006. Antimicrobial susceptibility patterns and staphylococcal cassette chromosome mec types of, as well as Panton-Valentine leukocidin occurrence among, methicillin-resistant *Staphylococcus aureus* isolates from children and adults in middle Tennessee. *J. Clin. Microbiol.*, 44(12): 4436-40.
- Majumder, D., J.N. Bordoloi, A.C. Phukan and J. Mahanta, 2001. Antimicrobial susceptibility pattern among methicillin resistant staphylococcus isolates in Assam. *Ind. J. Med. Microbiol.*, 19: 138-140.
- McDonald, M., 1997. The epidemiology of methicillin-resistant *Staphylococcus aureus*: Surgical relevance 20 years on. *Aust. N. Z. J. Surg.*, 67: 682-685.
- Mehta, A.P., C. Rodrigues, K. Sheth, S. Jani, A. Hakimiyan and N. Fazalbhoy, 1998. Control of methicillin resistant *Staphylococcus aureus* in a tertiary care centre-a five-year study. *J. Med. Microbiol.*, 16: 31-34.
- Metha, A.A., C.C. Rodrigues, R.R. Kumar, A.A. Rattan, H.H. Sridhar, V.V. Mattoo and V.V. Ginde, 1996. A pilot programme of MRSA surveillance in India. (MRSA surveillance study group). *J. Postgrad. Med.*, 42(1): 1-3.
- Moges, F., A. Genetu and G. Mengistu, 2002a. Antibiotic sensitivities of common bacterial pathogens in urinary tract infections at Gondar hospital, Ethiopia. *East Afr. Med. J.*, 79(3): 140-142.
- Moges, F., G. Mengistu and A. Genetu, 2002b. Multiple drug resistance in urinary pathogens at Gondar college of medical science hospital, Ethiopia. *East Afr. Med. J.*, 79(8): 415-419.
- NCCLS (National Committee for Clinical Laboratory Standards), 2002. Performance standards for antimicrobial disc susceptibility tests. 12th International Supplement; M100-S12, NCCLS, Wayne, PA.
- Olowe, O., K. Eniola, R. Olowe and A. Olayemi, 2007. Antimicrobial susceptibility and beta-lactamase detection of MRSA in Osogbo, SW, Nigeria. *Nat. Sci.*, 5(3): 44-48.
- Omari, M.A., I.M. Malonza, J.J. Bwayo, A.N. Mutere, E.M. Murage, A.K. Mwatha and J.O. Ndinya-Achola, 1997. Patterns of bacterial infections and antimicrobial susceptibility at the Kenyatta National Hospital, Nairobi, Kenya. *East Afr. Med. J.*, 74: 134-137.
- Paradisi, F., G. Corti and D. Messeri, 2001. Antibiotic therapy. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. *Med. Clin. North Am.*, 85: 1-17.
- Patrick, E.A., K. Shivnarine, H.S. William and M. Michele, 2006. Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus* isolates from Trinidad and Tobago. *Ann. Clin. Microbiol. Antimicrob.*, 5(16): 1-6.

- Price, M.F., E.M. Mollie and E.W. John, 1998. Prevalence of methicillin-resistant *Staphylococcus aureus* in a dermatology outpatient population. Southern Med. J., 91: 369-71.
- Pulimood, T.B., M.K. Lalitha, M.V. Jesudson, R. Pandian and J.J. Selwyn, 1996. The spectrum of antimicrobial resistance among methicillin resistant *Staphylococcus aureus* (MRSA) in a tertiary care in India. Ind. J. Med. Res., 103: 212-215.
- Qureshi, A.H., S. Rafi, S.M. Qureshi and A.M. Ali, 2004. The current susceptibility patterns of methicillin resistant *Staphylococcus aureus* to conventional anti *Staphylococcus* antimicrobials at Rawalpindi. Pak. J. Med. Sci., 20: 361-364.
- Rajaduraiipandi, K., K.R. Mani, K. Panneerselvam, M. Mani, M. Bhaskar and P. Manikandan, 2006. Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus*: A multicentric study. Ind. J. Med. Microbiol., 24(1): 34-38.
- Rohrer, S., M. Bischoff, J. Rossi and B. Berger-Bächi, 2003. Mechanisms of Methicillin Resistance. In: Fluit, A.C. and F.J. Schmitz (Eds.), MRSA. Current Perspectives. Caister Academic Press, Wymondham, pp: 31-53.
- Saikia, L., R. Nath, B. Choudhary and M. Sarkar, 2009. Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus* in Assam. Ind. J. Crit. Care Med., 13(3): 156-158.
- Sanjana, R.K., S. Rajesh, C. Navin and Y.I. Singh, 2010. Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus* (MRSA) in CMS-teaching hospital: A preliminary report. J. Col. Med. Sci. Nepal., 6(1): 1-6.
- Tahnkiwale, S., S. Roy and S. Jalgaonkar, 2002. Methicillin resistant among isolates of *Staphylococcus aureus*: Antibiotic sensitivity pattern and phage typing. Ind. J. Med. Sci., 56: 330-334.
- Urassa, W.K., E.A. Haule, C. Kagoma and N. Langeland, 1999. Antimicrobial susceptibility of *S.aureus* strains at muhimbili medical center, Tanzania. East Afr. Med. J., 76: 693-695.
- Yohannes, M., E. Work and B. Bahrie, 1999. In vitro susceptibility of staphylococci to chlorhexidine and antibiotics. Eth. J. Health Dev., 13(3): 223-227.
- Zinn, C.S., H. Westh, V.T. Rosdahl and Sarisa Study Group, 2004. An international multicenter study of antimicrobial resistance and typing of hospital *Staphylococcus aureus* isolates from 21 laboratories in 19 countries or states. Microb. Drug Resist., 10: 160-168.